Gibbs: AI can boost profitability without massive infrastructure

Erin Gibbs, Chief Equity Strategist at SlateStone, sees opportunity in small and mid caps as rate cuts and growth improve. She highlights biotech approvals as a key 2026 catalyst, with Neurocrine a top pick.